Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.91 USD
Change Today -0.52 / -5.51%
Volume 82.7K
VCYT On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Open
$9.24
Previous Close
$9.43
Day High
$9.53
Day Low
$8.07
52 Week High
09/9/14 - $12.77
52 Week Low
11/14/14 - $6.01
Market Cap
246.5M
Average Volume 10 Days
80.9K
EPS TTM
$-1.42
Shares Outstanding
27.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the Percepta Bronchial Genomic Classifier, a lung cancer test that would identify patients with non-diagnostic bronchoscopy results whose nodules are at low risk of being cancerous. Veracyte, Inc. serves endocrinologists; radiologists; and ear, nose, and throat physicians. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

167 Employees
Last Reported Date: 03/25/15
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $300.0K
Chief Operating Officer
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

veracyte inc (VCYT) Key Developments

Veracyte, Inc. Appoints Dr. Neil M. Barth as Chief Medical Officer

Veracyte, Inc. announced the appointment of Neil M. Barth, M.D., F.A.C.P., as chief medical officer, effective immediately. Dr. Barth has more than 30 years of experience providing and directing patient care for healthcare-provider organizations and diagnostics companies. Most recently, he served as chief medical officer for Agendia NV. Prior to that, Dr. Barth served as chief medical officer for Ambry Genetics.

Veracyte, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015 ; Reiterates Guidance for the Year 2015

Veracyte, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $11,908,000, loss from operations of $9,074,000, net loss and comprehensive loss of $9,136,000 or $0.35 per basic and diluted share compared to the revenue of $8,677,000, loss from operations of $6,561,000, net loss and comprehensive loss of $6,655,000 or $0.31 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported revenue of $23,126,000, loss from operations of $16,627,000, net loss and comprehensive loss of $16,746,000 or $0.69 per basic and diluted share compared to the revenue of $16,153,000, loss from operations of $13,136,000, net loss and comprehensive loss of $13,329,000 or $0.63 per basic and diluted share for the same period a year ago. The company reiterated its 2015 annual revenue guidance of $48 million to $53 million, as well as its forecast to achieve annual Afirma GEC test volume in the range of 19,000 to 21,000.

Veracyte, Inc. to Report Q2, 2015 Results on Aug 13, 2015

Veracyte, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $8.91 USD -0.52

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $22.93 USD -0.61
Genomic Health Inc $26.35 USD -1.17
PDI Inc $2.06 USD -0.0199
Rosetta Genomics Ltd $2.43 USD +0.01
Trovagene Inc $5.72 USD -0.23
View Industry Companies
 

Industry Analysis

VCYT

Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERACYTE INC, please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.